Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | SRC | P12931 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL449666 | 1.00 | NPSR1 (0.44) | NPSR1LMNAMAPK1SRCCYP2D6 | |
| Ethylenediamine SCHEMBL2218952 | 0.90 | ADRA2C (0.40) | NPSR1LMNAMAPK1CYP2D6ALDH1A1 | |
| Ethylenediamine SCHEMBL7109144 | 0.90 | ADRA2C (0.40) | NPSR1LMNAMAPK1CYP2D6ALDH1A1 | |
| SCHEMBL10455652 | 0.76 | NPSR1 (0.43) | NPSR1LMNAMAPK1SRCCYP2D6 | |
| SCHEMBL4387215 | 0.76 | ALDH1A1 (0.43) | NPSR1LMNASRCCYP2D6ALDH1A1 | |
| SCHEMBL4387218 | 0.76 | ALDH1A1 (0.43) | NPSR1LMNASRCCYP2D6ALDH1A1 | |
| SCHEMBL10455650 | 0.76 | NPSR1 (0.43) | NPSR1LMNAMAPK1SRCCYP2D6 | |
| SCHEMBL329145 | 0.74 | NPSR1 (0.41) | NPSR1LMNAMAPK1SRCCYP2D6 | |
| SCHEMBL9283942 | 0.74 | NPSR1 (0.41) | NPSR1LMNAMAPK1SRCCYP2D6 | |
| SCHEMBL9283953 | 0.74 | NPSR1 (0.41) | NPSR1LMNAMAPK1SRCCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 211 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240408041-A1 | COMPOSITIONS AND METHODS FOR TREATING CANNABINOID HYPEREMESIS SYNDROME | HABBOUSHE JOSEPH (US) | 2024-12-12 | — | — | US | claimed |
| EP-4237427-A1 | ANTIBACTERIAL CYCLOPEPTIDES TARGETING ACINETOBACTER AND OTHER GRAM-NEGATIVE PATHOGENS | University of Utah Research Foundation (US) | 2023-09-06 | — | — | EP | claimed |
| CN-116670151-A | Antibacterial cyclic peptides targeting acinetobacter and other gram negative pathogens | 犹他大学研究基金会 | 2023-08-29 | — | — | CN | claimed |
| WO-2022094273-A1 | ANTIBACTERIAL CYCLOPEPTIDES TARGETING ACINETOBACTER AND OTHER GRAM-NEGATIVE PATHOGENS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2022-05-05 | — | — | WO | claimed |
| WO-2021140526-A1 | MUTANT PENICILLIN G ACYLASES OF ACHROMOBACTER CCM4824 | FERMENTA BIOTECH LIMITED (IN) | 2021-07-15 | — | — | WO | claimed |
| CN-107523219-B | Chemical Mechanical Polishing (CMP) of cobalt-containing substrates | 弗萨姆材料美国有限责任公司 | 2020-12-29 | — | — | CN | claimed |
| US-10745589-B2 | Chemical mechanical polishing (CMP) of cobalt-containing substrate | VERSUM MATERIALS US, LLC (US) | 2020-08-18 | — | — | US | claimed |
| US-20200061155-A1 | COMPOSITIONS AND METHODS FOR TREATING LYNX2 DISORDERS | OPHIDION INC. | 2020-02-27 | — | — | US | claimed |
| US-20190172720-A1 | Chemical Mechanical Polishing (CMP) of Cobalt-Containing Substrate | VERSUM MATERIALS US, LLC (US) | 2019-06-06 | — | — | US | claimed |
| EP-3257910-B1 | CHEMICAL MECHANICAL POLISHING (CMP) COMPOSITION, METHOD AND SYSTEM FOR COBALT-CONTAINING SUBSTRATE | VERSUM MAT US LLC (US) | 2019-03-27 | — | — | EP | claimed |
| WO-2010048095-A2 | TREATMENT AND/OR PREVENTION OF INNER EAR CONDITIONS BY MODULATION OF A METABOTROPIC GLUTAMATE RECEPTOR | HOUSE EAR INSTITUTE (US) | 2010-04-29 | — | — | WO | claimed |
| US-7309719-B1 | Storage stability; gabapentin and pregabalin, and neutral alpha -amino acid | WARNER LAMBERT COMPANY, LLC (US) | 2007-12-18 | — | — | US | claimed |
| EP-1077692-B1 | AMINO ACID STABILIZED GABAPENTIN AND PREGABALIN PREPARATIONS AND PROCESS FOR PREPARING THE SAME | WARNER LAMBERT CO (US) | 2004-07-28 | — | — | EP | claimed |
| EP-1274670-A1 | METHOD FOR THE PRODUCTION OF AROMATIC OR HETEROAROMATIC ALDEHYDES OR KETONES BY OXIDATIVE DECARBOXYLATION | DSM Fine Chemicals Austria Nfg GmbH & Co KG (AT) | 2003-01-15 | — | — | EP | claimed |
| EP-0848064-B1 | New antibiotic, Feglymycine, process for its preparation and use of the same | HOECHST AG (DE) | 2001-11-14 | — | — | EP | claimed |
| WO-2001079147-A1 | METHOD FOR THE PRODUCTION OF AROMATIC OR HETEROAROMATIC ALDEHYDES OR KETONES BY OXIDATIVE DECARBOXYLATION | DSM FINE CHEMICALS AUSTRIA NFG GMBH & CO KG (AT) | 2001-10-25 | — | — | WO | claimed |
| EP-1077692-A1 | AMINO ACID STABILIZED GABAPENTIN AND PREGABALIN PREPARATIONS AND PROCESS FOR PREPARING THE SAME | Warner-Lambert Company LLC (US) | 2001-02-28 | — | — | EP | claimed |
| WO-1999059573-A9 | STABILIZED PHARMACEUTICAL PREPARATIONS OF GAMMA-AMINOBUTYRIC ACID DERIVATIVES AND PROCESS FOR PREPARING THE SAME | WARNER LAMBERT CO (US) | 2000-05-04 | — | — | WO | claimed |
| WO-1999059573-A1 | STABILIZED PHARMACEUTICAL PREPARATIONS OF GAMMA-AMINOBUTYRIC ACID DERIVATIVES AND PROCESS FOR PREPARING THE SAME | WARNER-LAMBERT COMPANY (US) | 1999-11-25 | — | — | WO | claimed |
| EP-0164026-A1 | Process for the preparation of optically active glycine derivatives | BEECHAM GROUP PLC (GB) | 1985-12-11 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240408041-A1 | COMPOSITIONS AND METHODS FOR TREATING CANNABINOID HYPEREMESIS SYNDROME | CNR2, TRPV1, CNR1 | NPSR1 67/4885LMNA 2374/4885MAPK1 3201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.